Introduction {#section1-2192568217708776}
============

The anterior approach to the cervical spine using Smith-Robinson technique has been commonly used for the treatment of cervical discopathies.^[@bibr1-2192568217708776],[@bibr2-2192568217708776]^ Although the anterior approach is believed to be a relatively safe and effective procedure, it has been associated with complications such as dysphagia, dysphonia, airway compromise, and other tissue injuries.^[@bibr3-2192568217708776][@bibr4-2192568217708776][@bibr5-2192568217708776]--[@bibr6-2192568217708776]^

Dysphagia is an unpleasant condition and the most common complication after anterior cervical approach with a reported incidence rate of 1% to 79%, starting early in the postoperative course.^[@bibr7-2192568217708776][@bibr8-2192568217708776]--[@bibr9-2192568217708776]^ Although the etiology of dysphagia after anterior cervical spine surgery is not fully understood and there are many discrepancies in the findings of various studies, some factors such as local tissue edema, recurrent laryngeal nerve palsy, retraction of midline structures during the surgery, and prevertebral soft tissue swelling (PSTS) have been proposed.^[@bibr7-2192568217708776],[@bibr10-2192568217708776]^

Airway compromise is the most serious complication, associated with pharyngeal edema, as well as hematoma, angioedema, cerebrospinal fluid leak, and graft displacement.^[@bibr11-2192568217708776][@bibr12-2192568217708776][@bibr13-2192568217708776][@bibr14-2192568217708776][@bibr15-2192568217708776]--[@bibr16-2192568217708776]^ Although a rare complication, airway compromise is life-threatening as it could lead to reintubation, tracheostomy, or death.^[@bibr5-2192568217708776],[@bibr17-2192568217708776]^

Corticosteroids are known anti-inflammatory agents that inhibit the production of inflammatory prostaglandins and cytokines. Since major adverse outcomes after anterior approach are attributable to pharyngeal edema, it has been assumed that steroids can reduce the incidence of complications.^[@bibr5-2192568217708776]^ The aim of this systematic review is to evaluate the current evidence regarding the efficacy and safety of steroids in reducing the complications of the anterior cervical spine surgery.

Methods {#section2-2192568217708776}
=======

Protocol {#section3-2192568217708776}
--------

This systematic review was designed according to the guidelines of Cochrane Handbook for Systematic Reviews of Interventions (v. 5.1.0),^[@bibr18-2192568217708776]^ method guideline for systematic reviews in the Cochrane Back and Neck (CBN) group \[formerly Cochrane Back Review Group (CBRG)\],^[@bibr19-2192568217708776],[@bibr20-2192568217708776]^ and the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)^[@bibr21-2192568217708776][@bibr22-2192568217708776]--[@bibr23-2192568217708776]^ statement.

Eligibility Criteria {#section4-2192568217708776}
--------------------

We included all studies with a control group including randomized controlled trials (RCTs), controlled clinical trials, cohort studies, and case-control studies. The target population was patients of any age who underwent anterior cervical discectomy and fusion (ACDF) or anterior cervical corpectomy and fusion with one- or multiple-level fusion and received corticosteroids to prevent complications following the surgery. We excluded studies that used cervical epidural steroid injections as a diagnostic or therapeutic modality to relieve radiculopathy or neck pain before the surgery. Animal studies were also excluded.

Literature Search and Information Sources {#section5-2192568217708776}
-----------------------------------------

We performed a systematic search of the literature on July 10, 2016, using the following electronic databases without any restrictions on language or date of publications: MEDLINE (via OvidSP and PubMed), Embase, and Cochrane EBM (CENTRAL, DSR, and DARE). The complete search strategy is presented in the [appendix](#app1-2192568217708776){ref-type="app"}. Main search keywords were "anterior," "cervical vertebrae," "cervical," "neck," "intervertebral disc," "spinal decompression," "disc degeneration," "disc displacement," "disc herniation," "radiculopathy," "myelopathy," "spinal fusion," "arthrodesis," "discectomy," "glucocorticoids," and "steroids." Unpublished records were not considered in this review.

Study Selection {#section6-2192568217708776}
---------------

Two authors (SAZ and SBJ) screened all titles and abstracts independently. Full texts of relevant articles were obtained and assessed for eligibility. To select the articles, we used a discussion and consensus method at each step, and in case of disagreement, a third reviewer (AA) was consulted. We also screened the reference lists of included articles and relevant reviews for possible inclusions.

Data Items and Collection Process {#section7-2192568217708776}
---------------------------------

Two independent reviewers (SAZ and SBJ) used a predetermined form to extract the following information: study design, type of anterior procedure, demographic information, number of operated levels, inclusion/exclusion criteria for each study, dosage of the corticosteroid drug, and outcome variables. The rate of disagreement between the 2 extractors was 1%.

Outcome variables considered in this review were dysphagia/odynophagia, PSTS, airway compromise, length of hospital stay, steroid-related complications, and fusion rate.

Risk of Bias {#section8-2192568217708776}
------------

The risk of bias was independently assessed by 2 authors (SAZ and SBJ). Disagreements were resolved with consensus or consultation with a third reviewer (AA). For randomized studies, we used the 13-item criteria recommended by the Cochrane Back and Neck (CBN).^[@bibr19-2192568217708776],[@bibr20-2192568217708776]^ This tool contains 5 domains of bias, including selection bias (criteria 1, 2, and 9), performance bias (criteria 3, 4, 10, and 11), detection bias (criteria 5 and 12), attrition bias (criteria 6 and 7), and reporting bias (criterion 8). There is also a 13th criterion, which covers any potential bias that is not detected with previous items.^[@bibr20-2192568217708776]^ For nonrandomized studies, the 12-item criteria of Methodological Index for Non-Randomized Studies (MINORS) were used.^[@bibr24-2192568217708776]^ Each criterion is scored from 0 to 2, and the highest possible score for comparative studies is 24. This tool is proved to be valid and reliable to evaluate interventional studies.^[@bibr24-2192568217708776][@bibr25-2192568217708776]--[@bibr26-2192568217708776]^

A pilot test of the risk of bias assessment was performed on a set of similar articles. The Review Manager (RevMan) Version 5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) was used for assessment of the risk of bias and production of related tables.

Data Synthesis {#section9-2192568217708776}
--------------

Meta-analysis was not feasible due to the heterogeneity of studies.

Results {#section10-2192568217708776}
=======

Study Selection {#section11-2192568217708776}
---------------

Our search yielded 556 results. Six additional titles were identified through hand-searching of the reference lists ([Figure 1](#fig1-2192568217708776){ref-type="fig"}). Of the 31 full-text articles included in the primary screening stage, 9 studies (total population: 246 414) were eligible for further consideration: 7 RCTs^[@bibr16-2192568217708776],[@bibr27-2192568217708776][@bibr28-2192568217708776][@bibr29-2192568217708776][@bibr30-2192568217708776][@bibr31-2192568217708776]--[@bibr32-2192568217708776]^ and 2 nonrandomized studies (one cohort^[@bibr33-2192568217708776]^ and one case-control study^[@bibr34-2192568217708776]^). The other 22 articles were excluded because they were case reports,^[@bibr13-2192568217708776],[@bibr35-2192568217708776][@bibr36-2192568217708776][@bibr37-2192568217708776][@bibr38-2192568217708776]--[@bibr39-2192568217708776]^ studies without a control group for steroid,^[@bibr40-2192568217708776][@bibr41-2192568217708776][@bibr42-2192568217708776][@bibr43-2192568217708776][@bibr44-2192568217708776]--[@bibr45-2192568217708776]^ seminar abstracts,^[@bibr46-2192568217708776][@bibr47-2192568217708776]--[@bibr48-2192568217708776]^ reviews,^[@bibr49-2192568217708776],[@bibr50-2192568217708776]^ commentaries,^[@bibr51-2192568217708776],[@bibr52-2192568217708776]^ or studies without sufficient data on steroid use.^[@bibr53-2192568217708776][@bibr54-2192568217708776]--[@bibr55-2192568217708776]^ [Table 1](#table1-2192568217708776){ref-type="table"} shows characteristics of the included studies.

![PRISMA flow diagram.](10.1177_2192568217708776-fig1){#fig1-2192568217708776}

###### 

Characteristics of Included Studies.

![](10.1177_2192568217708776-table1)

  Author, Year                                   Study Design                 Procedure                                                                                                Patients/Levels                                       Levels                                                 Mean Age, Years (Range)                               FU (Range)       Inclusion/Exclusion Criteria                                                                                                                                                                                                                                                           Steroid
  ---------------------------------------------- ---------------------------- -------------------------------------------------------------------------------------------------------- ----------------------------------------------------- ------------------------------------------------------ ----------------------------------------------------- ---------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------
  Pedram (2003)^[@bibr27-2192568217708776]^      Prospective RCT              ACDF, ACCF, Isolated discectomy, Isolated fusionPlate fixation: Y                                        236 C:158 S:78                                        ---                                                    C: 47 ± 15.3 (15-88) S: 47 ± 12.3 (17-83)             36 h             Inclusion: patients requiring exclusively anterior operation of the cervical spine                                                                                                                                                                                                     Methylprednisolone (IV), 1 mg/kg at 0, 12, and 24 h postop
  Emery (2009)^[@bibr28-2192568217708776]^       Prospective RCT              ACCF, 2-4 levelsFusion: fibular strut graftPlate fixation: N                                             66 C: 31 S: 35                                        II: 24 III: 38 IV: 4                                   ---                                                   ---              Inclusion: cervical stenosis with cord compression at multiple levels                                                                                                                                                                                                                  Dexamethasone (IV), 0.3 mg/kg before the incision, followed by 0.15 mg/kg at 8 and 16 h later
  Lee (2011)^[@bibr16-2192568217708776]^         Prospective RCT              ACDF, 1-2 levelsFusion: PEEK cage filled with autologous cancellous bonePlate fixation: Y                50 C: 25 S: 25                                        I: 29 II: 21                                           C: 50.9 S: 54.3                                       21.6 m (16-32)   Inclusion: radiculopathy or myelopathy requiring 1- or 2-level ACDF Exclusion: fusion \>3 segments, revision surgery, corpectomy, trauma, infection, tumor, general metabolic diseases (such as rheumatoid arthritis, diabetes, and chronic heart and renal diseases)                  Triamcinolone (RF), 40 mg in a morcellized collagen sponge
  Nam (2013)^[@bibr29-2192568217708776]^         Prospective RCT              ACDF, 1 levelFusion: allogeneic cortical bone and DBMPlate fixation: Y                                   62 C: 22 S1: 20 S2: 20                                I: 62                                                  C: 48.8 ± 7.6 S1: 45.6 ± 7.3 S2: 46.9 ± 8.6           5 d              Inclusion: cervical radiculopathy requiring single-level ACDF Exclusion: radiculopathy requiring ACDF ≥2 levels, myelopathic disease, cervical trauma, corpectomy                                                                                                                      Dexamethasone (IV), S1: 10, 5, 5 mg; S2: 20, 10, 10 mg, at 0, 24, and 48 h postop
  Song (2014)^[@bibr30-2192568217708776]^        Prospective RCT              ACDF, 3-4 levelsPlate fixation: Y                                                                        40 C: 20 S: 20                                        C III: 10 IV: 10 S III: 10 IV: 10                      C: 57.3 ± 11.0 (29-77) S: 59.9 ± 10.3 (42-74)         3 m              Inclusion: degenerative cervical disease requiring multilevel ACDF confirmed with preoperative plain radiographs, computed tomography, and magnetic resonance imaging Exclusion: trauma other than that related to the operative procedure that could influence soft-tissue swelling   Methylprednisolone (IV), 250 mg at 0, 6, 12, and 24 h postop
  Jeyamohan (2015)^[@bibr31-2192568217708776]^   Prospective RCT              ACDF, 2-5 levelsFusion: carbon-fiber cage filled with HA, collagen and autologous BMAPlate fixation: Y   112 C: 56 S: 56                                       II: 28 III: 40 IV: 42 V: 2                             C: 55 S: 54                                           24 m             Inclusion: age ≥18 y, cervical spondylosis requiring surgical treatment at ≥2 motion segments, ventrally approachable vertebral levels Exclusion: pregnancy, chronic preop steroid use, coma, incapacitation, unable to provide consent, allergy to dexamethasone or related drugs     Dexamethasone (IV), 0.2 mg/kg intraoperative dose followed by 0.06 mg/kg doses at 6, 12, and 24 h later
  Edwards (2016)^[@bibr32-2192568217708776]^     Prospective RCT              ACDF, 1-3 levelsFusion: PEEK spacer, local bone graft, and BMP-2Plate fixation: Y                        50 C: 23 S: 27                                        C I: 30.4% II: 69.6% S I: 55.6% II: 33.3% III: 11.1%   C: 53.5 S: 54.0                                       1 m              Inclusion: age 18-70 y, elective 1-, 2-, or 3-level ACDF, primary or revision cases Exclusion: nondegenerative pathology (fracture, tumor, infection, etc), ≥4-level ACDF, combined lumbar fusion surgery, circumferential surgical approaches                                         Methylprednisolone (RF), 40 mg/cc in a 1 × 3 cm collagen sponge
  Cancienne (2016)^[@bibr33-2192568217708776]^   Retrospective cohort         ACDF, 1-2 levels                                                                                         200 000 C: 198 230 S: 1770                            ---                                                    Age \<70 C: 66.8% S: 69.8% Age \>80 C: 6.2% S: 5.4%   3 m              Inclusion: ACDF procedures using CPT codes 22554, 22551, 22585, and 63076 in addition to the ICD-9 procedure code 810.2                                                                                                                                                                Local injection of Triamcinolone acetonide, 1 or 10 mg Methylprednisolone acetate, 20 or 40 or 80 mg
  ACDF, ≥3 levels                                45 754 C: 45 432 S: 322      ---                                                                                                      Age \<70 C: 61.8% S: 60.1% Age \>80 C: 6.3% S: 5.6%                                                                                                                                                                                                                                                                                                                                                                                                                        
  Koreckij (2016)^[@bibr34-2192568217708776]^    Retrospective case-control   ACDF, 2-4 levelsFusion: Cortical allograft packed with DBM and local bonePlate fixation: Y               44 C: 22 S: 22                                        C II: 10 III: 11 IV: 1 S II: 10 III: 11 IV: 1          C: 57.6 ± 9.9 S: 55.1 ± 7.9                           3 m              Inclusion: ACDF for radiculopathy or myelopathy Exclusion: Single-level procedures, revision surgery, trauma, infection, tumor, autoimmune-related diseases (ie, rheumatoid arthritis)                                                                                                 Methylprednisolone (RF), 80 mg in a morcellized collagen sponge

Abbreviations: ACCF, anterior cervical corpectomy and fusion; ACDF, anterior cervical discectomy and fusion; BMA, bone marrow aspirate; BMP, bone morphogenetic protein; C, control/sham/placebo group; CPT, Current Procedural Terminology; d, day(s); DBM, demineralized bone matrix; FU, follow-up; h, hour(s); HA, hydroxyapatite; ICD-9, International Classification of Disease, 9th Revision; IV, intravenous; m, month(s); N, no; PEEK, polyether ether ketone; RF, retropharyngeal; S, steroid group; Y. yes.

Risk of Bias {#section12-2192568217708776}
------------

We assessed the risk of bias for 7 randomized studies with CBN criteria ([Figure 2](#fig2-2192568217708776){ref-type="fig"}). The 2 extractors primarily disagreed on 14 out of 91 items, all of which were consequently resolved through discussion and consensus. Allocation concealment, random sequence generation, and blinding (especially personnel and outcome assessors) were reported in less than 50% of the trials ([Figure 3](#fig3-2192568217708776){ref-type="fig"}).

![Summary of risk of bias for randomized studies (the 13-item criteria of the Cochrane Back and Neck group): review authors' judgments about each risk of bias items for each included study. Plus sign (green): low risk; Minus sign (red): high risk; Question mark (yellow): unclear risk of bias.](10.1177_2192568217708776-fig2){#fig2-2192568217708776}

![Summary of risk of bias for randomized studies (the 13-item criteria of the Cochrane Back and Neck group): review authors' judgments about each risk of bias items across all included studies.](10.1177_2192568217708776-fig3){#fig3-2192568217708776}

We used MINORS tool for the 2 nonrandomized studies ([Figure 4](#fig4-2192568217708776){ref-type="fig"}). Of the total 24 items, 4 items required further discussion and consultation with a third reviewer. Blind evaluation of the endpoints (item 5), loss to follow-up (item 7), and prospective calculation of the study size (item 8) were not addressed in both studies.

![Summary of risk of bias for nonrandomized studies (MINORS criteria): review authors' judgments about each risk of bias items for each included study. 0: Not reported; 1: Reported but inadequate; 2: Reported and adequate.](10.1177_2192568217708776-fig4){#fig4-2192568217708776}

Outcomes {#section13-2192568217708776}
--------

A detailed summary of the outcome measures is presented in [Table 2](#table2-2192568217708776){ref-type="table"}.

###### 

Summary of Findings.

![](10.1177_2192568217708776-table2)

  Author, Year                                   Dysphagia/Odynophagia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Prevertebral Soft Tissue Swelling                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Airway Compromise                                                                                                                                                                                                                                                                                                                                                                                                                                                       Length of Hospital Stay                                                                                                                                          Postoperative Steroid Need                                                                                           Steroid-Related Complications                                                                                                  Fusion
  ---------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------
  Pedram (2003)^[@bibr27-2192568217708776]^      Subjective unpleasant sensation during swallowing, odynophagia, dysphagia or impaired swallowing during postop: C: 130 (82.3%) S: 56 (71.8%) NS Objective fiber optic ENT exam for pharyngolaryngeal lesions, 24-36 h postop:Absence of lesion   C: 12 (7.59%)   S: 32 (41%)   *P* \< .0001Slight   C: 63 (39.8%)   S: 37 (47.4%)   NSModerate   C: 59 (37.3%)   S: 8 (10.2%)   *P* \< .0001Severe   C: 22 (13.9%)   S: 1 (1.2%)   *P* \< .0001Very severe   C: 2 (1.26%)   S: 0 (0%)   *P* \< .0001 Overall: lesions were more frequent in group C, *P* \< .0001, RR: 1.57 (CI = 1.3-1.9)                                                                                 ---                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Respiratory distress C: 2 (both had a revision surgery for drainage of cervical hematoma) S: 0                                                                                                                                                                                                                                                                                                                                                                          ---                                                                                                                                                              C: 88 (55%), 66 (41.7%) local nebulization of a corticosteroid, 22 (13.9%) methylprednisolone IV S: 0 *P* \< .0001   ---                                                                                                                            ---
  Emery (2009)^[@bibr28-2192568217708776]^       ---                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ---                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Delayed extubation (\>1 day) C: 6 (19.3%) S: 5 (14.2%) NS, *P* = .22                                                                                                                                                                                                                                                                                                                                                                                                    C: 4.645 d S: 4.371 d NS, *P* = .47                                                                                                                              ---                                                                                                                  ---                                                                                                                            ---
  Lee (2011)^[@bibr16-2192568217708776]^         VAS (odynophagia)Immediately postop   C: 5.3   S: 2.5   *P* = .0004 d postop   C: 4.6   S: 1.5   *P* = .0002 w postop   C: 3.5   S: 1.2   *P* = .000                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       PSTSI in C3-C5 on RGImmediately postop   C: 74.3%   S: 58.2%   *P* = .0042 d postop   C: 84.1%   S: 57.9%   *P* = .0004 d postop   C: 82.9%   S: 56.3%   *P* = .0002 w postop   C: 51.4%   S: 44.9%   *P* = .036                                                                                                                                                                                                                                                                                                                                                                                                        ---                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ---                                                                                                                                                              ---                                                                                                                  ---                                                                                                                            With RG and CT scan at last FU C: 24 (96%) S: 25 (100%)
  Nam (2013)^[@bibr29-2192568217708776]^         VAS (odynophagia)Immediately postop   C: 1.9 ± 0.8   S1: 1.9 ± 0.9   S2: 1.9 ± 0.7   NS, *P* = .9701 d postop   C: 3.0 ± 0.8   S1: 2.9 ± 1.0   S2: 3.0 ± 0.8   NS, *P* = .8102 d postop   C: 2.5 ± 1.0   S1: 2.5 ± 0.9   S2: 2.6 ± 1.1   NS, *P* = .9363 d postop   C: 2.0 ± 1.1   S1: 1.8 ± 0.9   S2: 2.0 ± 0.9   NS, *P* = .7924 d postop   C: 1.4 ± 1.0   S1: 1.2 ± 0.7   S2: 1.5 ± 0.7   NS, *P* = .3535 d postop   C: 1.0 ± 1.0   S1: 0.6 ± 0.6   S2: 1.0 ± 0.6   NS, *P* = .078                                                                                                                                                                                      PSTD in C1-C7 on RGImmediately postop   C: 1629 ± 229 cm^2^   S1: 1533 ± 224 cm^2^   S2: 1520 ± 226 cm^2^   NS, *P* = .2371 d postop   C: 1789 ± 267 cm^2^   S1: 1699 ± 258 cm^2^   S2: 1689 ± 248 cm^2^   NS, *P* = .3872 d postop   C: 1963 ± 338 cm^2^   S1: 1865 ± 318 cm^2^   S2: 1836 ± 321 cm^2^   NS, *P* = .4193 d postop   C: 1966 ± 302 cm^2^   S1: 1886 ± 282 cm^2^   S2: 1867 ± 282 cm^2^   NS, *P* = .5014 d postop   C: 1853 ± 301 cm^2^   S1: 1776 ± 307 cm^2^   S2: 1747 ± 251 cm^2^   NS, *P* = .4735 d postop   C: 1706 ± 335 cm^2^   S1: 1576 ± 292 cm^2^   S2: 1541 ± 305 cm^2^   NS, *P* = .202   VAS (dyspnea)Immediately postop   C: 1.4 ± 0.7   S1: 1.0 ± 0.6   S2: 0.9 ± 0.6   *P* = .0181 d postop   C: 2.4 ± 0.8   S1: 1.8 ± 0.7   S2: 1.9 ± 0.7   *P* = .0432 d postop   C: 2.5 ± 0.9   S1: 2.0 ± 0.8   S2: 1.9 ± 0.7   *P* = .0273 d postop   C: 1.6 ± 0.7   S1: 1.8 ± 0.7   S2: 1.8 ± 0.6   NS, *P* = .6954 d postop   C: 1.1 ± 0.8   S1: 1.0 ± 0.9   S2: 1.0 ± 0.7   NS, *P* = .8335 d postop   C: 0.6 ± 0.7   S1: 0.6 ± 0.7   S2: 0.5 ± 0.6   NS, *P* = .653   ---                                                                                                                                                              ---                                                                                                                  ---                                                                                                                            ---
  Song (2014)^[@bibr30-2192568217708776]^        Dysphagia with Bazaz scale1 d postop   C: 20 (100%) svr   S: 19 (95%) svr, 1 (5%) mod   NS, *P* = .3112 d postop   C: 14 (70%) svr, 6 (30%) mod   S: 7 (35%) svr, 13 (65%) mod *  P* = .0273 d postop   C: 8 (40%) svr, 12 (60%) mod   S: 4 (20%) svr, 11 (55%) mod, 5 (25%) mld   *P* = .0414 d postop   C: 4 (20%) svr, 13 (65%) mod, 3 (15%) mld   S: 8 (40%) mod, 12 (60%) mld   *P* = .0055 d postop   C: 14 (70%) mod, 6 (30%) mld   S: 4 (20%) mod, 14 (70%) mld, 2 (10%) none   *P* = .005                                                                                                                                                                         PSTS summation of C2-C7 on RG1 d postop   C: 95.5 ± 18.1 mm   S: 84.7 ± 17.1 mm   NS, *P* = .612 d postop   C: 103.5 ± 19.2 mm   S: 82.2 ± 14.6 mm *  P* \< .0013 d postop   C: 103.9 ± 21.8 mm   S: 79.4 ± 12.7 mm   *P* \< .0014 d postop   C: 108.9 ± 14.6 mm   S: 76.5 ± 12.7 mm   *P* \< .0015 d postop   C: 105 ± 14.3 mm   S: 78.2 ± 13.9 mm   *P* \< .0016 d postop   C: 107.8 ± 17.0 mm   S: 65.4 ± 3.6 mm   *P* \< .0017 d postop   C: 100.0 ± 19.0 mm   S: 73.5 ± 8.7 mm   NS, *P* = .091                                                                                                                    ---                                                                                                                                                                                                                                                                                                                                                                                                                                                                     C: 6.0 ± 1.02 d (range 4-7) S: 5.1 ± 0.7 d (range 4-7) *P* = .003                                                                                                ---                                                                                                                  None                                                                                                                           ---
  Jeyamohan (2015)^31^                           FOSS1 m postop   C: 0.66   S: 0.064   *P* = .0273 m postop   C: 0.261   S: 0.14   NS, *P* = .4456 m postop   C: 0.174   S: 0.2   NS, *P* = .76812 m postop   C: 0.1   S: 0.26   NS, *P* = .37524 m postop   C: 0.041   S: 0.115   NS, *P* = .333                                                                                                                                                                                                                                                                                                                                                                                                                           ---                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Airway compromise rate: 2.7%                                                                                                                                                                                                                                                                                                                                                                                                                                            ---                                                                                                                                                              C: 8 (14.3%) S: 1 (1.8%)                                                                                             ---                                                                                                                            CT scan6 m postop   C: 60%   S: 39.5%   *P* = .04712 m postop   C: 80%   S: 75%   NS, *P* = .5724 m postop   C: 95.2%   S: 92.7%   NS, *P* = .572
  Edwards (2016)^[@bibr32-2192568217708776]^     Number of patients *without* dysphagia1 d postop   C: 7 (30.4%)   S: 4 (14.8%)   NS, *P* = .3054 d postop   C: 3 (13.0%)   S: 16 (59.3%)   *P* = .0017 d postop   C: 5 (21.7%)   S: 16 (59.3%)   *P* = .01014 d postop   C: 7 (30.4%)   S: 18 (66.7%)   *P* = .02228 d postop   C: 6 (26.1%)   S: 15 (55.6%)   *P* = .047 Dysphagia with modified Bazaz scale1 d postop   C: 1.09 ± 0.900   S: 1.04 ± 0.649   NS, *P* = .8394 d postop   C: 1.74 ± 1.05   S: 0.52 ± 0.700 *  P* \< .0017 d postop   C: 1.43 ± 1.04   S: 0.56 ± 0.751 *  P* \< .00214 d postop   C: 1.39 ± 1.20   S: 0.52 ± 0.802   *P* = .00528 d postop   C: 1.35 ± 1.11   S: 0.59 ± 0.747   *P* = .012   ---                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Adverse airway events: C: 1 (4.3%), readmission for breathing difficulty S: 0 NS, *P* = .460                                                                                                                                                                                                                                                                                                                                                                            C: 24.42 h S: 24.97 h NS, *P* = .612                                                                                                                             C: 4 (17.4%) S: 1 (3.7%) NS, *P* = .167                                                                              None                                                                                                                           ---
  Cancienne (2016)^[@bibr33-2192568217708776]^   Incidence of dysphagia after 1-2 level ACDF within 90 days postop C: 16,582 (8.4%) S: 133 (7.5%) NS, *P* = .198 Incidence of dysphagia after ≥3-level ACDF within 90 days postop C: 6631 (14.6%) S: 29 (9.0%) *P* = .005                                                                                                                                                                                                                                                                                                                                                                                                                                                   ---                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ---                                                                                                                                                                                                                                                                                                                                                                                                                                                                     For 1-2 level ACDF within 90 days postop C: 2 ± 2.2 d S: 1 ± 1.1 d *P* \< .0001 For ≥3-level ACDF within 90 days postop C: 3 ± 2.8 d S: 2 ± 1.3 d *P* \< .0001   ---                                                                                                                  Combined rates of infection and wound breakdown within 90 days postop C: 1.6% S: 1.7% NS, *P* = .717, OR: 0.9 (CI = 0.7-1.3)   ---
  Koreckij (2016)^[@bibr34-2192568217708776]^    Dysphagia with Bazaz scale6 w postop   C: 40.9% svr, 27.3% mod, 9.1% mld, 22.7% none   S: 14.3% svr, 14.3% mod, 9.5% mld, 61.9% none   *P* = .0083 m postop   C: 23.8% svr, 19% mod, 9.5% mld, 47.6% none   S: 9.5% mod, 14.3% mld, 76.2% none   *P* = .022 Dysphagia with EAT-106w postop   C: 28.6% nl   S: 59.1% nl   NS, *P* = .0673 m postop   C: 42.9% nl   S: 81.8% nl   *P* = .012                                                                                                                                                                                                                                                                                 PSTSI in C3-C7 on RG1 d postop   C: 1.19 ± 0.24   S: 1.33 ± 0.26   NS, *P* = .096 w postop   C: 1.58 ± 0.70   S: 1.62 ± 0.36   2NS, *P* = .93                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ---                                                                                                                                                                                                                                                                                                                                                                                                                                                                     C: 2.2 ± 1.9 d S: 1.27 ± 0.6 d *P* = .03                                                                                                                         ---                                                                                                                  ---                                                                                                                            ---

Abbreviations: C, control/sham/placebo group; CI, confidence interval; CT, computed tomography; d, day(s); FOSS, Functional Outcome Swallowing Scale; FU, follow-up; h, hour(s); JOA, Japanese Orthopaedic Association; mld, mild; mod, moderate; m, month; NDI, Neck Disability Index; nl, normal; NS, nonsignificant; OR, odds ratio; PSTD, prevertebral soft tissue density; PSTSI, prevertebral soft tissue swelling index; RF, retropharyngeal; RG, radiography; RR, relative risk; S, steroid group; SF-12, 12-Item Short-Form Health Survey; svr, severe; VAS, Visual Analogue Scale, w, week(s).

Dysphagia/Odynophagia {#section14-2192568217708776}
---------------------

In this series of studies, main assessment tools for dysphagia/odynophagia were the following:Bazaz scale, which has 4 grades including none (no dysphagia), mild (rare episodes of dysphagia with solid food), moderate (occasional difficulty swallowing foods such as bread or meat), and severe (frequent dysphagia with liquids and majority of foods).^[@bibr8-2192568217708776]^ The Bazaz scale has been widely used because of its simplicity; however, it has never been validated.^[@bibr56-2192568217708776]^ Among included studies, Song et al^[@bibr30-2192568217708776]^ and Koreckij et al^[@bibr34-2192568217708776]^ used this scale, and Edwards et al^[@bibr32-2192568217708776]^ applied a modified version.Eating Assessment Tool (EAT-10), a 10-item questionnaire with 0 to 4 points for each item (0 = no problem, 4 = severe problem) and maximum total of 40 points. A total score greater than 3 is indicative of dysphagia.^[@bibr57-2192568217708776]^ Koreckij et al^[@bibr34-2192568217708776]^ used this tool besides the Bazaz scale.Functional Outcome Swallowing Scale (FOSS) was administered in one study by Jeyamohan et al.^[@bibr31-2192568217708776]^ This scale defines different stages for dysphagia ranging from asymptomatic (stage 0) to non--oral feeding for all nutrition (stage V).^[@bibr58-2192568217708776]^The Visual Analogue Scale (VAS) was used by Lee et al^[@bibr16-2192568217708776]^ and Nam et al^[@bibr29-2192568217708776]^ for odynophagia.

Five RCTs reported that intravenous or local corticosteroids significantly reduce dysphagia after anterior spinal surgery.^[@bibr16-2192568217708776],[@bibr27-2192568217708776],[@bibr30-2192568217708776][@bibr31-2192568217708776]--[@bibr32-2192568217708776]^ Pedram et al^[@bibr27-2192568217708776]^ performed fiber-optic examination of the oropharynx, the hypopharynx, and the larynx. They found that pharyngolaryngeal lesions were significantly more severe in the control group during the first 36 hours after surgery. Lee et al^[@bibr16-2192568217708776]^ reported a lower VAS for odynophagia immediately after surgery and during the first 2 weeks. Song at al^[@bibr30-2192568217708776]^ monitored dysphagia with the Bazaz scale for the first 5 days after surgery. Although the severity of dysphagia was the same between the 2 groups in the first day, it was significantly reduced in the steroid group in postoperative days 2 to 5. Similarly, Edwards et al^[@bibr32-2192568217708776]^ found no significant difference in the modified Bazaz scale between steroid and control groups in the first day postoperative, but afterwards, a significant reduction of symptoms occurred in the steroid group, which remained through the 28 days of follow-up. Jeyamohan et al,^[@bibr31-2192568217708776]^ in a long-term follow-up (24 months) by FOSS, showed that the severity of dysphagia is significantly lower in the steroid group during the first month.

Of the 2 remaining RCTs, the one by Emery et al^[@bibr28-2192568217708776]^ did not have data regarding the swallowing problems, and the other by Nam et al^[@bibr29-2192568217708776]^ showed no significant difference in VAS scores for odynophagia between the control, low-dose, and high-dose steroid groups during the first 5 days after surgery. Their study was the only one that had a population of pure one-level procedure, while all other studies also included multilevel procedures.

Both the nonrandomized studies found positive effects of steroids on reducing the incidence or severity of dysphagia. Cancienne et al^[@bibr33-2192568217708776]^ in a cohort of 245 754 patients showed that incidence of dysphagia is lower within 90 days postoperatively in patients treated with steroids. However, this finding was only significant in ACDF ≥3-level fusion. Koreckij et al^[@bibr34-2192568217708776]^ reported a significant reduction in severity of dysphagia with EAT-10 and Bazaz scale at 1.5- and 3-month follow-up.

Prevertebral Soft Tissue Swelling {#section15-2192568217708776}
---------------------------------

Only 4 of the included studies reported PSTS and there were variations in their assessment methods. Lee et al^[@bibr16-2192568217708776]^ calculated the ratio of the anteroposterior diameter of each vertebral body to the prevertebral soft tissue thickness in lateral radiographs of cervical spine and reported a mean percentage of PSTS at C3-5 as PSTS index. Koreckij et al^[@bibr34-2192568217708776]^ used the same method; the only difference was that the PSTS index was calculated for C3-7. Nam et al^[@bibr29-2192568217708776]^ measured the prevertebral soft tissue density, an area of the prevertebral soft tissue (in cm^2^) from the lower border of C1 to the upper end plate of C7 in lateral radiographs. Song et al^[@bibr30-2192568217708776]^ measured the diameter of prevertebral tissue (in mm) in lateral view.

The effect of steroid administration on PSTS was concordant with the findings for dysphagia. Nam et al^[@bibr29-2192568217708776]^ found no significant difference in PSTS among groups within 5 days postoperative. Lee et al^[@bibr16-2192568217708776]^ and Song et al^[@bibr30-2192568217708776]^ found significant reduction in PSTS during the 2-week and 1-week follow-ups, respectively. Similar to the results for dysphagia, Song et al^[@bibr30-2192568217708776]^ reported a nonsignificant difference just for the first day postoperative and a significant effect afterwards.

The only discordance between the results of dysphagia assessment and PSTS was reported in the case-control study by Koreckij et al,^[@bibr34-2192568217708776]^ where they found no significant difference in PSTS but a significant reduction of dysphagia between the steroid and control groups.

Airway Compromise {#section16-2192568217708776}
-----------------

The results for this outcome were very limited and poorly reported. Emery et al^[@bibr28-2192568217708776]^ used delayed extubation (\>1 day) as an indicator of airway compromise and found no significant difference between the control and steroid groups. Edwards et al^[@bibr32-2192568217708776]^ reported no adverse airway events (prolonged intubation, reintubation, or readmission for breathing difficulty) in the steroid group and only one readmission for breathing difficulty in the control group, which was not statistically significant. Nam et al^[@bibr29-2192568217708776]^ conducted VAS score for dyspnea. Although they reported no significant effect of steroids on reduction of dysphagia and PSTS, dyspnea was significantly reduced in the steroid group during the first 2 days postoperative. However, there was no significant difference within the third to the fifth days postoperative.

Length of Hospital Stay {#section17-2192568217708776}
-----------------------

Both RCTs reporting hospitalization period found no difference between the steroid and control groups.^[@bibr28-2192568217708776],[@bibr32-2192568217708776]^ In contrast, both nonrandomized studies proved a significantly shorter hospital stay with steroid treatment.^[@bibr33-2192568217708776],[@bibr34-2192568217708776]^

Postoperative Steroid Need {#section18-2192568217708776}
--------------------------

This outcome was defined as the proportion of patients who required treatment with corticosteroids in the control group or required extra doses of steroid, additional to the main protocol, in the steroid group. Three studies reported this outcome to be higher in the control group compared with the steroid group, as follows: Pedram et al^[@bibr27-2192568217708776]^ (55% vs 0%, *P* \< .0001), Jeyamohan et al^[@bibr31-2192568217708776]^ (14.3% vs 1.8%), and Edwards et al^[@bibr32-2192568217708776]^ (17.4% vs 3.7%, *P* \> .05).

Steroid-Related Complications {#section19-2192568217708776}
-----------------------------

Song et al^[@bibr30-2192568217708776]^ followed the patients for 3 months for complications such as peptic ulcer disease or operation site infections and reported no complications. Likewise, Edwards et al^[@bibr32-2192568217708776]^ found no infection, delayed healing, or diabetes. Combined rates of infection and wound breakdown were measured by Cancienne et al^[@bibr33-2192568217708776]^ within 90 days postoperative. There was no significant difference between the control and steroid groups (1.6% vs 1.7%, respectively).

Fusion {#section20-2192568217708776}
------

Only 2 studies reported fusion rate. Lee et al^[@bibr16-2192568217708776]^ observed complete fusion at the latest follow-up (range 16-32 months) in the lateral radiographs and computed tomography scans of the patients treated with steroid, while they found one nonunion in the control group. Jeyamohan et al^[@bibr31-2192568217708776]^ performed computed tomography scans at 6, 12, and 24 months postoperation. The fusion rate was significantly lower in the steroid group compared with the control at the 6-month follow-up (39.5% vs 60%, respectively), whereas this difference disappeared at subsequent follow-ups (at 24 months, 92.7% vs 95.2%, respectively).

Discussion {#section21-2192568217708776}
==========

In this study, we reviewed the current evidence of steroid use in anterior cervical spine surgery. Seven RCTs, one case-control study, and one cohort study were included. The risk of bias assessment showed that the quality of studies was generally low, since both the nonrandomized studies were retrograde and only 2 out of 7 randomized studies had acceptable method of randomization.

Dysphagia significantly decreased with corticosteroids. This finding was confirmed by all studies except the one performed by Nam et al,^[@bibr29-2192568217708776]^ in which they reported no significant difference between the control and 2 steroid groups with different doses. This may be due to their limited inclusion criteria that only recruited patients with 1-level ACDF and excluded the procedures on 2 or more levels. Cancienne et al^[@bibr33-2192568217708776]^ found significant effects of steroids only in ACDF ≥3 levels; in contrast, Lee et al^[@bibr16-2192568217708776]^ showed that dysphagia was significantly lowered by steroids in 1- or 2-level ACDF. Despite some controversies, all studies proved steroids to be beneficial in prevention of dysphagia after anterior cervical procedures for more than 2 levels of fusion. This discrepancy implies the importance of steroid trials comparing the outcomes between single- and multilevel procedures. Furthermore, since there is no sufficient evidence on validity of most of the measures of dysphagia that were used in these studies, their findings must be interpreted with caution.

PSTS and airway compromise were reported in less than 50% of studies. PSTS was generally in accordance with findings of dysphagia. Airway compromise is not a common complication and was only reported in 3 studies. There was a vast variation in assessment methods and the results. Surprisingly, although Nam et al^[@bibr29-2192568217708776]^ determined no significant effect of steroids on reduction of dysphagia and PSTS, they reported a significantly lower VAS score for dyspnea in steroid group. The other 2 studies found no significant difference between the steroid group and controls in their assessments for airway compromise.^[@bibr28-2192568217708776],[@bibr32-2192568217708776]^

Two major concerns regarding the use of corticosteroids are steroid-related complications and reduced/delayed fusion. In those few studies that addressed these outcomes, no complications or long-term reduction of fusion rates were reported. However, as reported by Jeyamohan et al,^[@bibr31-2192568217708776]^ the fusion rate was significantly delayed in the steroid group at the 6-month follow-up. As the current evidence is not enough, it is necessary to appraise the effect of steroids on fusion rate in the forthcoming studies with long-term designs.

The form, dose, and type of corticosteroid drug, as well as the methods of outcome evaluation were different in the included studies. This heterogeneity made the data pooling and meta-analysis impossible. Further clinical trials with appropriate design and sample size are needed to reach a definite conclusion.

Conclusion {#section22-2192568217708776}
==========

Current literature consistently supports the use of steroids for prevention of complication such as dysphagia in patients undergoing anterior cervical spine surgery with fusion. However, these findings are limited by poor methodological quality of the studies, particularly by the indeterminate quality of the outcome measurement instruments. Furthermore, lack of comparisons between single- and multilevel surgeries and limited number of steroid trials that evaluate the fusion rate, airway compromise, and PSTS are the areas of concern that are recommended to be addressed in future studies.
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Search Strategy {#section23-2192568217708776}
===============

PubMed {#section24-2192568217708776}
------

(Anterior) AND ("Cervical Vertebrae"\[Mesh\] OR "Neck"\[Mesh\] OR cervical OR neck) AND ("Diskectomy"\[Mesh\] OR "Decompression, Surgical"\[Mesh\] OR "Intervertebral Disc"\[Mesh\] OR "Intervertebral Disc Degeneration"\[Mesh\] OR "Intervertebral Disc Displacement"\[Mesh\] OR "Discitis"\[Mesh\] OR "Radiculopathy"\[Mesh\] OR "Spinal Cord Diseases"\[Mesh\] OR discectomy OR diskectomy OR decompression OR corpectomy OR radiculopath\* OR myelopath\* OR radiculomyelopath\* OR radiculo-myelopath\* OR myeloradiculopath\* OR myelo-radiculopath\* OR diskitis OR discitis OR discopath\* OR ((disc\* OR disk\*) AND (degenerat\* OR displace\* OR hernia\*)) OR "Spinal Fusion"\[Mesh\] OR "Arthrodesis"\[Mesh\] OR fusion OR arthrodesis) AND ("Glucocorticoids"\[Mesh\] OR "Adrenal Cortex Hormones"\[Mesh\] OR "Steroids"\[Mesh\] OR "Dexamethasone"\[Mesh\] OR "Betamethasone"\[Mesh\] OR "Hydrocortisone"\[Mesh\] OR "Cortisone"\[Mesh\] OR "Prednisolone"\[Mesh\] OR "Methylprednisolone"\[Mesh\] OR "Methylprednisolone Hemisuccinate"\[Mesh\] OR "Triamcinolone"\[Mesh\] OR "Triamcinolone Acetonide"\[Mesh\] OR "Budesonide"\[Mesh\] OR "Fludrocortisone"\[Mesh\] OR "Fluprednisolone"\[Mesh\] OR "Paramethasone"\[Mesh\] OR glucocortic\* OR gluco-cortic\* OR corticosteroid\* OR cortico-steroid\* OR corticoid\* OR steroid\* OR corticotropin OR dexamethason\* OR dexametason\* OR betamethason\* OR betametason\* OR hydrocortison\* OR cortison\* OR predniso\* OR methylpredniso\* OR methyl-predniso\* OR triamcinolon\* OR budesonid\* OR fludrocortison\* OR fluprednisolon\* OR paramethason\*)

Embase {#section25-2192568217708776}
------

1.  \#1. anterior

2.  \#2. 'cervical spine'/exp

3.  \#3. 'neck'/exp

4.  \#4. cervical

5.  \#5. neck

6.  \#6. 'cervical spine'/exp OR 'neck'/exp OR cervical OR neck

7.  \#7. 'intervertebral diskectomy'/exp

8.  \#8. 'spinal cord decompression'/exp

9.  \#9. 'intervertebral disk'/exp

10. \#10. 'intervertebral disk degeneration'/exp

11. \#11. 'intervertebral disk hernia'/exp

12. \#12. 'radiculopathy'/exp

13. \#13. 'cervical myelopathy'/exp

14. \#14. Discectomy

15. \#15. Diskectomy

16. \#16. Decompression

17. \#17. corpectomy

18. \#18. radiculopath\*

19. \#19. myelopath\*

20. \#20. radiculomyelopath\*

21. \#21. 'radiculo myelopath\*'

22. \#22. myeloradiculopath\*

23. \#23. 'myelo radiculopath\*'

24. \#24. discopath\*

25. \#25. 'diskitis'/exp

26. \#26. Diskitis

27. \#27. Discitis

28. \#28. disc\* OR disk\*

29. \#29. degenerat\* OR displace\* OR hernia\*

30. \#30. disc\* OR disk\* AND (degenerat\* OR displace\* OR hernia\*)

31. \#31. 'anterior spine fusion'/exp

32. \#32. fusion

33. \#33. Arthrodesis

34. \#34. 'intervertebral diskectomy'/exp OR 'spinal cord decompression'/exp OR 'intervertebral disk'/exp OR 'intervertebral disk degeneration'/exp OR 'intervertebral disk hernia'/exp OR 'radiculopathy'/exp OR 'cervical myelopathy'/exp OR discectomy OR diskectomy OR decompression OR corpectomy OR radiculopath\* OR myelopath\* OR radiculomyelopath\* OR 'radiculo myelopath\*' OR myeloradiculopath\* OR 'myelo radiculopath\*' OR discopath\* OR 'diskitis'/exp OR diskitis OR discitis OR (disc\* OR disk\* AND (degenerat\* OR displace\* OR hernia\*)) OR 'anterior spine fusion'/exp OR fusion OR arthrodesis

35. \#35. 'glucocorticoid'/exp

36. \#36. 'steroid'/exp

37. \#37. 'corticosteroid'/exp

38. \#38. 'dexamethasone'/exp

39. \#39. 'betamethasone'/exp

40. \#40. 'hydrocortisone'/exp

41. \#41. 'cortisone'/exp

42. \#42. 'prednisolone'/exp

43. \#43. 'methylprednisolone'/exp

44. \#44. 'methylprednisolone sodium succinate'/exp

45. \#45. 'triamcinolone'/exp

46. \#46. 'triamcinolone acetonide'/exp

47. \#47. 'budesonide'/exp

48. \#48. 'fludrocortisone'/exp

49. \#49. 'fluprednisolone'/exp

50. \#50. 'paramethasone'/exp

51. \#51. glucocortic\*

52. \#52. 'gluco cortic\*'

53. \#53. corticosteroid\*

54. \#54. 'cortico steroid\*'

55. \#55. corticoid\*

56. \#56. steroid\*

57. \#57. Corticotropin

58. \#58. dexamethason\*

59. \#59. dexametason\*

60. \#60. betamethason\*

61. \#61. betametason\*

62. \#62. hydrocortison\*

63. \#63. cortison\*

64. \#64. predniso\*

65. \#65. methylpredniso\*

66. \#66. 'methyl predniso\*'

67. \#67. triamcinolon\*

68. \#68. budesonid\*

69. \#69. fludrocortison\*

70. \#70. fluprednisolon\*

71. \#71. paramethason\*

72. \#72. 'glucocorticoid'/exp OR 'steroid'/exp OR 'corticosteroid'/exp OR 'dexamethasone'/exp OR 'betamethasone'/exp OR 'hydrocortisone'/exp OR 'cortisone'/exp OR 'prednisolone'/exp OR 'methylprednisolone'/exp OR 'methylprednisolone sodium succinate'/exp OR 'triamcinolone'/exp OR 'triamcinolone acetonide'/exp OR 'budesonide'/exp OR 'fludrocortisone'/exp OR 'fluprednisolone'/exp OR 'paramethasone'/exp OR glucocortic\* OR 'gluco cortic\*' OR corticosteroid\* OR 'cortico steroid\*' OR corticoid\* OR steroid\* OR corticotropin OR dexamethason\* OR dexametason\* OR betamethason\* OR betametason\* OR hydrocortison\* OR cortison\* OR predniso\* OR methylpredniso\* OR 'methyl predniso\*' OR triamcinolon\* OR budesonid\* OR fludrocortison\* OR fluprednisolon\* OR paramethason\*

73. \#73. anterior AND ('cervical spine'/exp OR 'neck'/exp OR cervical OR neck) AND ('intervertebral diskectomy'/exp OR 'spinal cord decompression'/exp OR 'intervertebral disk'/exp OR 'intervertebral disk degeneration'/exp OR 'intervertebral disk hernia'/exp OR 'radiculopathy'/exp OR 'cervical myelopathy'/exp OR discectomy OR diskectomy OR decompression OR corpectomy OR radiculopath\* OR myelopath\* OR radiculomyelopath\* OR 'radiculo myelopath\*' OR myeloradiculopath\* OR 'myelo radiculopath\*' OR discopath\* OR 'diskitis'/exp OR diskitis OR discitis OR (disc\* OR disk\* AND (degenerat\* OR displace\* OR hernia\*)) OR 'anterior spine fusion'/exp OR fusion OR arthrodesis) AND ('glucocorticoid'/exp OR 'steroid'/exp OR 'corticosteroid'/exp OR 'dexamethasone'/exp OR 'betamethasone'/exp OR 'hydrocortisone'/exp OR 'cortisone'/exp OR 'prednisolone'/exp OR 'methylprednisolone'/exp OR 'methylprednisolone sodium succinate'/exp OR 'triamcinolone'/exp OR 'triamcinolone acetonide'/exp OR 'budesonide'/exp OR 'fludrocortisone'/exp OR 'fluprednisolone'/exp OR 'paramethasone'/exp OR glucocortic\* OR 'gluco cortic\*' OR corticosteroid\* OR 'cortico steroid\*' OR corticoid\* OR steroid\* OR corticotropin OR dexamethason\* OR dexametason\* OR betamethason\* OR betametason\* OR hydrocortison\* OR cortison\* OR predniso\* OR methylpredniso\* OR 'methyl predniso\*' OR triamcinolon\* OR budesonid\* OR fludrocortison\* OR fluprednisolon\* OR paramethason\*)

OVID {#section26-2192568217708776}
----

1.  1\. Anterior.mp.

2.  2\. Cervical Vertebrae/

3.  3\. Neck/

4.  4\. cervical.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

5.  5\. neck.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

6.  6\. 2 or 3 or 4 or 5

7.  7\. Diskectomy/

8.  8\. Decompression, Surgical/

9.  9\. Intervertebral Disc/

10. 10\. Intervertebral Disc Degeneration/ or Intervertebral Disc Displacement/

11. 11\. Discitis/

12. 12\. Radiculopathy/

13. 13\. Spinal Cord Diseases/

14. 14\. discectomy.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

15. 15\. diskectomy.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

16. 16\. decompression.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

17. 17\. corpectomy.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

18. 18\. discitis.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

19. 19\. diskitis.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

20. 20\. radiculopath\*.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

21. 21\. myelopath\*.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

22. 22\. radiculomyelopath\*.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

23. 23\. radiculo-myelopath\*.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

24. 24\. myeloradiculopath\*.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

25. 25\. myelo-radiculopath\*.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

26. 26\. discopath\*.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

27. 27\. disc\*.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

28. 28\. disk\*.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

29. 29\. degenerat\*.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

30. 30\. displace\*.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

31. 31\. hernia\*.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

32. 32\. Spinal Fusion/

33. 33\. Arthrodesis/

34. 34\. fusion.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

35. 35\. arthrodesis.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

36. 36\. 27 or 28

37. 37\. 29 or 30 or 31

38. 38\. 36 and 37

39. 39\. 7 or 8 or 9 or 10 or 12 or 14 or 15 or 16 or 17 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 32 or 33 or 34 or 35 or 38

40. 40\. Glucocorticoids/

41. 41\. Adrenal Cortex Hormones/

42. 42\. Steroids/

43. 43\. Dexamethasone/

44. 44\. Betamethasone/

45. 45\. Hydrocortisone/

46. 46\. Cortisone/

47. 47\. Prednisolone/

48. 48\. Methylprednisolone/

49. 49\. Methylprednisolone Hemisuccinate/

50. 50\. Triamcinolone/

51. 51\. Triamcinolone Acetonide/

52. 52\. Budesonide/

53. 53\. Fludrocortisone/

54. 54\. Fluprednisolone/

55. 55\. Paramethasone/

56. 56\. glucocortic\*.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

57. 57\. gluco-cortic\*.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

58. 58\. corticosteroid\*.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

59. 59\. cortico-steroid\*.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

60. 60\. corticoid\*.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

61. 61\. steroid\*.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

62. 62\. corticotropin.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

63. 63\. dexamethason\*.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

64. 64\. dexametason\*.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

65. 65\. betamethason\*.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

66. 66\. betametason\*.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

67. 67\. hydrocortison\*.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

68. 68\. cortison\*.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

69. 69\. predniso\*.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

70. 70\. methylpredniso\*.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

71. 71\. methyl-predniso\*.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

72. 72\. triamcinolon\*.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

73. 73\. budesonid\*.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

74. 74\. fludrocortison\*.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

75. 75\. fluprednisolon\*.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

76. 76\. paramethason\*.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]

77. 77\. 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76

78. 78\. 1 and 6 and 39 and 77
